SUGAR-MGH 2023 sulfonylurea and metformin response GWAS: trans-ancestry

Download summary statistics | README | Additional information

Publications

Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH.
Li JH, Brenner L, Kaur V, et al.
Diabetologia. 2023 Jul;66(7):1260-1272. doi: 10.1007/s00125-023-05922-7.
PMID: 37233759

Phenotypes

SULFONYLUREA RESPONSE:

  • Glucose at 30 min at V1
  • Glucose at 60 min at V1
  • Glucose at 90 min at V1
  • Glucose at 120 min at V1
  • Glucose at 180 min at V1
  • Glucose at 240 min at V1
  • Log (fasting glucose at V1 - trough glucose) over (time to glucose trough)
  • Log (glucose at 240 min - trough glucose) over (time to glucose trough)
  • Log of insulin at 30 min at V1
  • Log of insulin at 60 min at V1
  • Log of insulin at 90 min at V1
  • Log of insulin at 120 min at V1
  • Log of insulin at 180 min at V1
  • Log of insulin at 240 min at V1
  • Log of peak insulin at V1
  • Glucose minimum after glipizide treament
  • Time to insulin peak after glipizide treatment
  • Time to glucose minimum after glipizide treatment

METFORMIN RESPONSE:

  • Fasting glucose at V2
  • Fasting glucose at V2 minus fasting glucose at V1
  • Glucose at 30 min at V2
  • Glucose at 60 min at V2
  • Glucose at 120 min at V2
  • Log of fasting insulin at V2
  • Fasting insulin at V2 minus fasting insulin at V1
  • Log of insulin at 30 min at V2
  • Log of insulin at 60 min at V2
  • Log of insulin at 120 min at V2
  • Area under the curve of insulin at V2 adj fasting insulin at V2
  • HOMA-B at V2 minus HOMA-B at V1
  • HOMA-IR at V2 minus HOMA-IR at V1

Project

The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) is a pharmacogenetic study in which 890 individuals of diverse ancestries who were naive to type 2 diabetes (T2D) medications received a single-dose glipizide challenge and a short course of metformin, with the goal of comprehensively identifying novel genetic predictors of acute metformin and glipizide response in individuals at risk of T2D but naive to these medications.

Dataset ID
Huerta2023_SUGARMGH_Mixed